Apella Capital LLC Buys New Position in Alpha Tau Medical Ltd. $DRTS

Apella Capital LLC bought a new stake in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 382,284 shares of the company’s stock, valued at approximately $1,892,000. Apella Capital LLC owned approximately 0.45% of Alpha Tau Medical at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. acquired a new position in Alpha Tau Medical during the 3rd quarter valued at about $62,000. Bank of America Corp DE increased its holdings in shares of Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the period. Millennium Management LLC acquired a new position in shares of Alpha Tau Medical in the third quarter valued at about $170,000. Mariner LLC increased its holdings in shares of Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after purchasing an additional 80,129 shares during the period. Finally, Levin Capital Strategies L.P. increased its holdings in shares of Alpha Tau Medical by 6.3% in the third quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock valued at $923,000 after purchasing an additional 12,200 shares during the period. 2.65% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Citigroup increased their price objective on Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Alpha Tau Medical in a report on Tuesday, March 10th. Piper Sandler reissued a “neutral” rating and issued a $5.00 price objective on shares of Alpha Tau Medical in a report on Wednesday, March 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Alpha Tau Medical has a consensus rating of “Hold” and an average target price of $8.67.

Alpha Tau Medical Stock Up 4.5%

Alpha Tau Medical stock opened at $7.14 on Wednesday. The firm has a market cap of $605.61 million, a price-to-earnings ratio of -13.47 and a beta of 1.04. Alpha Tau Medical Ltd. has a 52 week low of $2.43 and a 52 week high of $8.60. The business’s 50-day moving average price is $7.19 and its 200 day moving average price is $5.58. The company has a quick ratio of 7.45, a current ratio of 7.45 and a debt-to-equity ratio of 0.08.

Alpha Tau Medical (NASDAQ:DRTS) last posted its earnings results on Monday, March 9th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, sell-side analysts anticipate that Alpha Tau Medical Ltd. will post -0.45 earnings per share for the current year.

Alpha Tau Medical Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.